We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Burning Rock Biotech Ltd | LSE:BNR | London | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.35 | 0 | 01:00:00 |
TIDMBNR
RNS Number : 9746X
Blenheim Natural Resources PLC
27 February 2017
27 February 2017
Blenheim Natural Resources Plc
("Blenheim" or the "Company")
Extension of Option to Invest in Lithium Project in Mali
Blenheim announces that its option to acquire a 30 per cent interest in the Dieba exploration permit in Southern Mali ("Dieba") has been extended until 31 March 2017.
Blenheim's Chairman Chris Ells commented, "Xantus Inc ("Xantus") has agreed to extend Blenheim's option to acquire a 30 per cent interest in the Dieba exploration permit so that we can consider how Blenheim can further collaborate and work with Xantus to broaden the Company's investments in assets with lithium potential. We are also working to identify and appraise other lithium opportunities and we continue to evaluate potential strategic investments in good projects and assets in the wider natural resources and agribusiness sectors, in line with our investment strategy."
Background to the option agreement with Xantus
Xantus holds interests in four licences in Mali, including Dieba, and four in Niger, all with geology conducive to lithium deposits. The Dieba exploration permit is located about 150km south of the Malian capital, Bamako. Dieba is adjacent to Birimian Limited's Bougouni Lithium Project and Xantus and Blenheim believe that Dieba may host similar lithium-rich pegmatites. The option agreement with Xantus gives Blenheim the right to acquire a 30 per cent interest in Dieba from Xantus for a consideration of GBP175,000 in cash, (which will be used by Xantus to fund exploration at Dieba) and 60,000,000 ordinary shares of 0.1 pence each in the capital of the Company. Blenheim paid GBP25,000 to secure this option. The original expiry date of the option was 28 February 2017, but Xantus has now agreed to extend the option until 31 March 2017.
Ends
For further information please contact:
Blenheim Natural Resources +44 (0) 1622 Chris Ells Plc 844601 Colin Aaronson/Jamie Barklem/ Daniel Grant Thornton UK +44 (0) 20 Bush LLP 7383 5100 +44 (0) 1483 Nick Emerson SI Capital Ltd 413500 Lucy Williams Peterhouse Corporate +44 (0) 20 / Duncan Vasey Finance Limited 7469 0932 +44 (0) 20 Colin Rowbury Cornhill Capital Limited 7710 9610
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FURPGUGPPUPMGQM
(END) Dow Jones Newswires
February 27, 2017 11:22 ET (16:22 GMT)
1 Year Burning Rock Biotech Chart |
1 Month Burning Rock Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions